Develops controlled-release drug delivery technologies, focusing on preventing surgical site infections and other medical applications.
PolyPid Ltd., headquartered in Petah Tikva, Israel, is an advanced biopharmaceutical company specializing in the development, manufacturing, and commercialization of innovative products based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform. The company focuses on addressing critical unmet medical needs through its groundbreaking technology, which enables precise delivery and sustained release of therapeutic agents.
At the forefront of PolyPid's pipeline is D-PLEX100, its lead product candidate currently undergoing Phase III clinical trials. D-PLEX100 is designed for the prevention of surgical site infections (SSIs), targeting both sternal (bone) and abdominal (soft tissue) regions. This innovative formulation aims to significantly reduce the incidence of SSIs following surgical procedures, offering potential benefits to patients and healthcare providers alike.
Founded in 2008, PolyPid has built a solid foundation of scientific expertise and strategic partnerships to advance its pioneering platform. With a strong commitment to improving patient outcomes through effective infection prevention strategies, the company continues to innovate and expand its portfolio, positioning itself as a leader in the field of biopharmaceuticals.